ArticleBMC cancer2025
Refining compression therapy for the prevention of chemotherapy-induced peripheral neuropathy in breast cancer patients: a sub-analysis of patient-reported discomfort and usability.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of taxane-based chemotherapy in breast cancer patients. Previous findings suggest that compression therapy may be a safe and effective preventive strategy against CIPN. However, patient-reported comfort and usability aspects of such therapy remain underexplored. This sub-analysis aimed to evaluate patient-reported discomfort and pressure associated with compression therapy and explore potential usability barriers to compliance.
methodsThis sub-analysis of a Phase I single-arm, open-label trial focused on patient-reported outcomes related to the subjective experience of compression therapy using double-layered surgical gloves and stockings during taxane administration. Parameters such as discomfort, pressure, pain, and itch in hands and feet were collected via questionnaires from 10 patients receiving neoadjuvant or adjuvant chemotherapy. Post hoc univariable analyses were conducted to explore potential factors associated with discomfort scores.
resultsMost patients reported minimal discomfort (mean hand discomfort score: 1.8; mean foot discomfort score: 2.2) and no pain in hands or feet during therapy. Mean perceived pressure scores were generally rated as “slight” to “mild,” though higher in calves (3.0) than toes (2.6) or fingertips (2.8). No statistically significant associations were identified between discomfort scores and other reported factors, though a positive trend between pain and discomfort was observed. Free-text responses highlighted that application and removal of double-layer compression garments posed greater challenges than physical discomfort itself.
conclusionsCompression therapy using standard gloves and stockings appears tolerable and feasible for CIPN prevention. However, ease of application rather than discomfort may be the primary barrier to patient compliance. Future designs should prioritize usability and fit to ensure sustained adherence, especially in clinical settings.
trial registrationjRCTs032210221, registered on 4 August 2021.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.